Martin Edelman, chair of hematology and oncology at Fox Chase Cancer Center, presented the results of a clinical study testing palbociclib, a drug used to treat breast cancer, in patients with squamous non-small cell lung cancer at the American Society of Clinical Oncology.

AstraZeneca and MedImmune, its global biologics research and development arm, announced positive results for the phase III PACIFIC trial, a randomized, double-blinded, placebo-controlled multi-center trial of Imfinzi (durvalumab) as sequential treatment in patients with locally-advanced, unresectable non-small cell lung cancer who had not progressed following standard platinum-based chemotherapy concurrent with radiation therapy.

A new study offers a treatment option for patients with recurrent lung cancer, who historically have been considered ineligible for curative treatment.

Researchers in the Schools of Medicine and Engineering at Vanderbilt University have discovered a proteomic “signature” from the airways of heavy smokers that could lead to better risk assessment and perhaps new ways to stop lung cancer before it starts.

Cota, a data and technology platform for value-based precision medicine, released a lung cancer study conducted jointly with Novartis that compares real-world practice patterns of genetic testing of EGFR/ALK mutations versus published guidelines.

Data from phase III trial showed that Tagrisso (osimertinib) second-line therapy improved progression-free survival by 5.7 months, compared with standard platinum-based doublet chemotherapy (Hazard Ratio [HR]=0.3).